Press & media
CELYSTRA Pharma news and media resources.
News and media resources from CELYSTRA Pharma.
Latest News
-
–
CELYSTRA Pharma at the 25th Annual Market Access Summit in Toronto
Paul Lévesque, President, CEO and Co-Founder of CELYSTRA Pharma, spoke at the 25th Annual Market Access Summit. He discussed launch strategy in Canada amid long approval timelines and global uncertainty.
-
Health Canada Approves DAWNZERA® (donidalorsen) for the Prevention of Hereditary Angioedema Attacks
Approval marks CELYSTRA Pharma’s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.
-
Paul Levesque Featured on the NPC (National Pharmaceutical Congress) Podcast
Listen to the conversation our President and CEO, Paul Levesque, had on the National Pharmaceutical Congress (NPC) Podcast, covering Canadian biotech, rare disease policy, and AI as an healthcare accelerator.
-
Québec Becomes First Province to Cover TRYNGOLZA® (olezarsen) for Familial Chylomicronemia Syndrome
Coverage under Québec’s public drug plan provides access to the first therapy approved by Health Canada for this rare genetic disease.
-
Interview with Paul Lévesque on ICI RDI’s “Zone Économie”
Watch an interview our president, Paul Lévesque, gave to Gérald Filion on his show Zone Économie on ICI RDI.
-
Fonds de solidarité FTQ Invests in CELYSTRA Pharma
To support the launch of CELYSTRA Pharma, the Fonds de solidarité FTQ has joined the company’s founders and other investors in a $20 million financing round.
-
CELYSTRA Pharma: Trio of Industry Veterans Launches Quebec Biopharmaceutical Company to Bring Innovative Treatments to Canada
Three pharmaceutical industry veterans today announced the creation of CELYSTRA Pharma, a new Quebec-based biopharmaceutical company specializing in the introduction of innovative treatments to Canada.
Members of the media are invited to contact our communications team directly with any questions, interview requests, or requests for additional documentation.